Recombinant Mouse AIFM3 Protein Pre-coupled Magnetic Beads

• Cat.No.: AIFM3-413M-B
• Product Overview: The Recombnant protein was conjugated to magnetic beads. This ready-to-use, pre-coupled magnetic beads are in uniform particle size and narrow size distribution with large surface area, which is conducive to convenient and fast capture target molecules with high specificity and achieve magnetic separation. This product can be equipped with automation equipment for high-throughput operations.

Specification

• Source: HEK293
• Species: Mouse
• Form: Solution
• Particle size: ~2 μm
• Beads Surface: Hydrophilic
• Capacity: > 200 pmol rabbit IgG/ mg beads
• Applications: Immunoassay, In vitro diagnostics, cell sorting, Immunoprecipitation/Co-precipitation, Protein/antibody separation and purification.
• Stability: Stable for at least 6 months from the date of receipt of the product under proper storage and handling conditions.
• Storage: 2-8℃. Do not to freeze thaw the Beads
• Concentration: 10mg beads/mL
• Storage Buffer: PBS buffer

Gene Information

• Gene Name: Aifm3 apoptosis-inducing factor, mitochondrion-associated 3 [ Mus musculus ]
• Official Symbol: AIFM3
• Gene ID: 72168
• mRNA Refseq: NM_175178.3
• Protein Refseq: NP_780387.2
• UniProt ID: Q3TY86

Reviews

06/30/2019

Its remarkable purity, consistency, and stability make it the perfect candidate to drive my research forward and produce precise and dependable results.

02/08/2019

the manufacturer of the AIFM3 protein offers exceptional technical support, reinforcing the overall excellence of their product.

04/01/2015

Their expert assistance effectively addresses any challenges or inquiries that may arise during my experiments, ensuring a seamless workflow and the successful resolution of any issues.

02/16/2015

The AIFM3 protein presents itself as an outstanding choice that surpasses my expectations in terms of quality and suitability for my experimental requirements.

Q&As

Is there any evidence supporting the involvement of AIFM3 in cancer?

Yes, AIFM3 has been shown to be upregulated in various cancers, including breast cancer and lung cancer, and its dysregulation has been implicated in cancer progression and metastasis.

What diseases are associated with AIFM3 dysregulation?

Dysregulation of AIFM3 has been implicated in various diseases, including cancer, Alzheimer's disease, and Parkinson's disease.

Can AIFM3 be used as a biomarker for disease diagnosis or prognosis?

It is possible that AIFM3 could be used as a biomarker for disease diagnosis or prognosis in the future. However, more research is needed to validate its potential as a biomarker. For example, a recent study has found that AIFM3 expression is decreased in the blood of patients with chronic obstructive pulmonary disease, suggesting that it could be a potential biomarker for this disease.

How is AIFM3 related to other AIF family proteins?

AIFM3 is a member of the AIF (Apoptosis-Inducing Factor) family of proteins, which also includes AIF and AIFM1. AIFM3 shares some structural and functional similarities with other AIF family proteins, but they have distinct roles in regulating mitochondrial function and cell death processes.

How is AIFM3 regulated at the molecular level?

AIFM3 expression is regulated by various transcription factors and epigenetic modifications. For example, the transcription factor NRF2 promotes AIFM3 expression by binding to its promoter region. Histone acetylation and DNA methylation also play a role in the regulation of AIFM3 expression.

Can AIFM3 be used as a biomarker for cancer diagnosis or prognosis?

There is currently no evidence supporting the use of AIFM3 as a biomarker for cancer diagnosis or prognosis. However, its dysregulation in cancer suggests that it may be a target for cancer therapy.

Are there any ongoing studies investigating the role of AIFM3 in disease?

Yes, there are ongoing studies investigating the role of AIFM3 in various diseases. For example, a recent study has found that AIFM3 expression is decreased in the brains of patients with Alzheimer's disease, suggesting that AIFM3 may play a role in the pathogenesis of this disease. Other studies are investigating the potential of AIFM3 as a therapeutic target for mitochondrial diseases and neurological disorders.

Can AIFM3 mutations cause mitochondrial diseases?

Yes, mutations in the AIFM3 gene have been associated with various mitochondrial diseases, such as mitochondrial encephalomyopathy and mitochondrial DNA depletion syndrome. These diseases are characterized by defects in mitochondrial function and energy metabolism.

How is AIFM3 expression regulated?

AIFM3 expression is regulated at the transcriptional level by various transcription factors, including HIF-1α and NF-κB.

Is there any evidence suggesting the involvement of AIFM3 in aging?

Yes, AIFM3 has been shown to be downregulated during aging, and its dysregulation has been implicated in aging-related degeneration and cellular senescence.

Can AIFM3 be a potential therapeutic target for mitochondrial diseases or neurological disorders?

Yes, targeting AIFM3 can be a potential therapeutic strategy for mitochondrial diseases or neurological disorders. For example, increasing AIFM3 expression or activity could improve mitochondrial function and energy metabolism in patients with mitochondrial diseases. In contrast, inhibiting AIFM3 activity could be beneficial in neurological disorders where excessive AIFM3 activity is detrimental, such as in epilepsy.

What techniques are used to study AIFM3?

Various techniques can be used to study AIFM3, including genetic and epigenetic analyses, protein expression and purification, cell culture and functional assays, and mouse models. For example, to study the role of AIFM3 in mitochondrial function, researchers can use techniques such as mitochondrial membrane potential analysis, respiration assays, and ATP production assays.

Are there any known mutations in the AIFM3 gene associated with human diseases?

Yes, mutations in the AIFM3 gene have been associated with various diseases, including autism spectrum disorders and X-linked intellectual disability.

Is AIFM3 a potential target for drug development?

Yes, AIFM3 is a potential target for drug development in various diseases, including cancer and neurodegenerative diseases. However, extensive research is needed to determine the therapeutic potential and safety of targeting AIFM3.